GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,432.00GBp
15 Sep 2014
Price Change (% chg)

-9.00p (-0.62%)
Prev Close
1,441.00p
Open
1,430.00p
Day's High
1,439.00p
Day's Low
1,427.50p
Volume
7,695,295
Avg. Vol
8,353,967
52-wk High
1,709.00p
52-wk Low
1,365.00p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.49
Market Cap (Mil.): £69,883.30
Shares Outstanding (Mil.): 4,849.64
Dividend: 19.00
Yield (%): 5.55

Financials

  GSK.L Industry Sector
P/E (TTM): 14.82 32.65 33.52
EPS (TTM): 0.97 -- --
ROI: 18.08 18.10 17.33
ROE: 75.85 18.80 18.19
Search Stocks

Exclusive: GSK China consumer healthcare unit linked to DOJ probe in 2012

SHANGHAI/WASHINGTON - A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.

09 Sep 2014

UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

BRIEF-GSK, GOLD, COPD foundation to form expert governance board for COPD assessment test

* GSK, GOLD and COPD Foundation announce formation of a new external expert governance board for COPD assessment test

08 Sep 2014

BRIEF-GSK, Gilead drug combo helps in pulmonary arterial hypertension

LONDON, Sept 8 - GlaxoSmithKline and Gilead Sciences release:

08 Sep 2014

BRIEF-GSK announces publication of positive study results for Mepolizumab

* Publication positive study results mepolizumab Source text for Eikon: For more, click on Further company coverage:

08 Sep 2014

Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

Drug and vaccine makers in race against Ebola

* GSK vaccine clinical trials under way, data by year-end

05 Sep 2014

India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden

MUMBAI - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product.

01 Sep 2014

India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden

MUMBAI, Sept 1 - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product.

01 Sep 2014

Ebola vaccine from GSK fast-tracked into clinical trials

LONDON/NEW YORK - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

28 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks